Alzheimer’s disease is a progressive, multifactorial neurodegenerative disorder that evolves over time. At RenuMemo Therapeutics, our research is guided by the belief that effective therapeutic strategies must address multiple, interconnected disease drivers rather than isolated targets.
Our research strategy is anchored by biological insights derived from prior human clinical observations, biomarkers, and define a rational combination hypothesis.
These insights guide compound selection and study design, while our therapeutic programs are advanced through rigorous preclinical and translational development.
We integrate pharmacology, disease biology, and translational models to bridge research insights with preclinical validation. Our approach emphasizes mechanistic relevance, CNS exposure, and dose-appropriate combination design to support development-ready programs.
Beyond multi-target coverage, we prioritize combinations where individual compounds are expected to interact synergistically—amplifying therapeutic impact at clinically feasible exposures. We evaluate synergy and optimize the ratio of doses, aiming to identify combinations where the whole is meaningfully greater than the sum of its parts.
Research activities at RenuMemo are structured to support clear development milestones rather than exploratory discovery alone. Translational validation directly informs program advancement toward IND-enabling development.
Our research efforts are currently centered on RM02, a synergy-oriented small-molecule combination program designed to translate complex Alzheimer’s disease biology into a development-ready therapeutic candidate.
Additional programs may be generated over time through the same research framework as evidence matures and development milestones are achieved.